公开(公告)号：US11090328B2

公开(公告)日：2021-08-17

申请号：US16030955

申请日：2018-07-10

申请人： DePuy Mitek, LLC

发明人： Julia Hwang ,  Dongling Su ,  Julius Lopez

IPC分类号： A61K31/728 ,  A61K31/737 ,  A61M5/19 ,  A61M5/20 ,  A61K9/00 ,  A61K31/7008

摘要： Compositions and methods are provided for treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluronic acid (“HA”), in combination with a lyophilized second component that is effective to at least temporarily reduce the viscosity of the HA. In an exemplary embodiment, the second component is one or more glycosaminoglycans (“GAG”), such as chondroitin sulfate (“CS”), including CS4 and/or CS6, dermatan sulfate, heparin, heparan sulfate, and keratan sulfate. The composition can optionally include other joint supplements, such as glucosamine (“GlcN”).

公开(公告)号：US20180311272A1

公开(公告)日：2018-11-01

申请号：US16030955

申请日：2018-07-10

申请人： DePuy Mitek, LLC

发明人： Julia Hwang ,  Dongling Su ,  Julius Lopez

IPC分类号： A61K31/728 ,  A61K9/00 ,  A61K31/737 ,  A61K31/7008 ,  A61M5/20 ,  A61M5/19

CPC分类号： A61K31/728 ,  A61K9/0019 ,  A61K31/7008 ,  A61K31/737 ,  A61M5/19 ,  A61M5/2066 ,  A61K2300/00

摘要： Compositions and methods are provided for treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluronic acid (“HA”), in combination with a lyophilized second component that is effective to at least temporarily reduce the viscosity of the HA. In an exemplary embodiment, the second component is one or more glycosaminoglycans (“GAG”), such as chondroitin sulfate (“CS”), including CS4 and/or CS6, dermatan sulfate, heparin, heparan sulfate, and keratan sulfate. The composition can optionally include other joint supplements, such as glucosamine (“GlcN”)

公开(公告)号：US20130178827A1

公开(公告)日：2013-07-11

申请号：US13750148

申请日：2013-01-25

申请人： DEPUY MITEK, LLC

发明人： Julia Hwang ,  Dongling Su ,  Julius Lopez

IPC分类号： A61M5/19

CPC分类号： A61K31/728 ,  A61K9/0019 ,  A61K31/7008 ,  A61K31/737 ,  A61M5/19 ,  A61M5/2066 ,  A61K2300/00

摘要： Compositions and methods are provided for treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluraonic acid (“HA”), in combination with a lyophilized second component that is effective to at least temporarily reduce the viscosity of the HA. In an exemplary embodiment, the second component is one or more glycosaminoglycans (“GAG”), such as chondroitin sulfate (“CS”), including CS4 and/or CS6, dermatan sulfate, heparin, heparan sulfate, and keratan sulfate. The composition can optionally include other joint supplements, such as glucosamine (“GlcN”)

摘要翻译： 提供组合物和方法用于治疗关节病，例如骨关节炎和/或与之相关的疼痛。 组合物和方法利用第一组分，即透明质酸（“HA”）与冻干的第二组分组合，其有效地至少暂时降低HA的粘度。 在一个示例性实施方案中，第二组分是一种或多种糖胺聚糖（“GAG”），例如硫酸软骨素（“CS”），包括CS4和/或CS6，硫酸皮肤素，肝素，硫酸乙酰肝素和硫酸角质素。 组合物可任选地包括其它联合补充剂，例如葡糖胺（“GlcN”）

公开(公告)号：US20140343012A1

公开(公告)日：2014-11-20

申请号：US14287809

申请日：2014-05-27

申请人： DePuy Mitek, LLC

发明人： Julia HWANG ,  Dongling Su ,  Julius Lopez

IPC分类号： A61K31/728 ,  A61K31/7008 ,  A61K9/00 ,  A61K31/737

CPC分类号： A61K31/728 ,  A61K9/0019 ,  A61K31/7008 ,  A61K31/737 ,  A61M5/19 ,  A61M5/2066 ,  A61K2300/00

摘要： Compositions and methods are provided for treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluraonic acid (“HA”), in combination with a lyophilized second component that is effective to at least temporarily reduce the viscosity of the HA. In an exemplary embodiment, the second component is one or more glycosaminoglycans (“GAG”), such as chondroitin sulfate (“CS”), including CS4 and/or CS6, dermatan sulfate, heparin, heparan sulfate, and keratan sulfate. The composition can optionally include other joint supplements, such as glucosamine (“GlcN”)

摘要翻译： 提供组合物和方法用于治疗关节病，例如骨关节炎和/或与之相关的疼痛。 组合物和方法利用第一组分，即透明质酸（“HA”）与冻干的第二组分组合，其有效地至少暂时降低HA的粘度。 在一个示例性实施方案中，第二组分是一种或多种糖胺聚糖（“GAG”），例如硫酸软骨素（“CS”），包括CS4和/或CS6，硫酸皮肤素，肝素，硫酸乙酰肝素和硫酸角质素。 组合物可任选地包括其它联合补充剂，例如葡糖胺（“GlcN”）